Validation of a Low-cost Platelet-Rich Plasma (PRP)
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 15 Sept 2023
- Ended
- 10 Oct 2024
- Type of study
- Interventional
- Treatments tested
- Intra-Articular knee injection of LC-PRP
- Record updated
- 17 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Patients of any adult age with symptomatic Kellgren-Lawrence (K-L) score 1-3 knee OA, based on radiographs within the last six months
- Patients must have failed at least six weeks of conventional conservative treatments (such as medication or physical therapy)
- Patients with bilateral knee OA will only be eligible if both knees fit the criteria; each knee will count separately
Who cannot take part
- Recent (last two years) knee surgery,
- Prior orthobiologic injection(s) into the knee,
- Oral steroids consumed within the last three months
- Active systemic infection requiring antibiotics, or local infection at the site of injection,
- Known thrombocytopenia (platelets under 50,000), thrombocythemia (platelets over 1,000,000), known platelet disorder (ITP, TTP, or Lowe syndrome)
- Known major axial deviation (over 30 degrees)
- Non-ambulatory patients,
- Patients seeking care with active litigation pending
- Body mass index (BMI) over 40
- Injection into the affected joint within the last six months
Where in United States
- University of Utah Orthopedic CenterSalt Lake City, United States
About the trial
What the trial wants to find out
Knee osteoarthritis is an extremely common and debilitating condition, more common in women, with an estimated global prevalence of 16%, and as high as 50% by the age of 80. Current management of knee osteoarthritis (OA) revolves around conservative treatments- biomechanical interventions, intra-articular injections, exercise, self-management and education, oral or topical medications, strength training, and weight management - or surgical management. For injection therapies, corticosteroids remain the standard of care; approximately 84% of sports medicine physicians perform these knee injections at least monthly, reporting a median range of 11-20 injections per month. Multiple detrimental effects of corticosteroid injections are well-known, including alterations of the hypothalamic-pituitary-adrenal axis, blood glucose levels, bone turnover, inflammatory response, blood pressure, and psychologic well-being. Thus, alternative therapies are of the utmost importance.
Read full original descriptionShow less
Platelet-Rich Plasma (PRP) is an injectable preparation of a patient's blood that can be used for numerous conditions and has received significant attention over the past several years for its potential application for the treatment of pain and functional impairment due to knee OA. Systematic reviews of randomized-controlled trials have demonstrated equivalent-to-superior treatment outcomes associated with the use of intra-articular PRP compared to placebo, hyaluronic acid, and corticosteroid. Furthermore, use of intra-articular PRP is associated with a very low rate of adverse events and is likely safer than injectable corticosteroids. Concerns that have limited a wider use of PRP include two main concerns - an uncertainty regarding the current evidence base due to study-related bias, heterogeneity, and lack of reporting standards; and second, more importantly, the main issue remains high cost.
The group in the trial
- Directly Address Two Concerns - Proper Reporting of PRP Composition and Greatly Decreasing CostOther group
As socioeconomic inequity directly relates to disability related to knee Osteoarthritis (OA), limiting the cost of treatment is of the utmost importance to ensure appropriate delivery of care to all patients. As PRP is currently not covered by the vast majority of public and private payors, patients are required to pay for the injections out of pocket, with an average cost of $714 per injection (as high as $2,092). Furthermore, research studies relating to PRP are often expensive due to the cost of the traditional method of extracting PRP, generally with commercial kits, and thus limited in scope. The investigators have developed and implemented a low-cost PRP (LC-PRP) preparation technique and have safely performed the injections on hundreds of patients with knee OA.
Treatment: Intra-Articular knee injection of LC-PRP
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 November 2025